Clasp Therapeutics’ novel T cell engagers could offer advantages over others in this class of cancer immunotherapies. The startup is based on the research of Johns Hopkins University scientist Bert Vogelstein.
We all know that certain behaviors like smoking, spending too much time in the sun, drinking excessively or an unhealthy diet can put us at risk for developing cancer. But according to some new research published in Science, unlucky, random cell mutation is the reason behind two thirds of cancer cases. Cristian Tomasetti and Bert […]
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.